We expect that recent developments in functional high-throughput screening including cell-based fluorescent screens for K+ channel activity will enable the identification of new KCNN4 K+ channel activators that may be useful as lead compounds for CF drug development [46], [47], [49]. The gene discussed is KCNN4; the disease is cystic fibrosis.